Skip to content

萨瓦拉制药

US · SVRA #3247 按市值排名
4.45 -0.29 -6.12%
实时 - 追踪5344个代码 - 心跳于152秒前 · 2026-10-16 20:01

最新新闻

  • 评级变动
    Guggenheim Initiates Savara(SVRA.US) With Buy Rating, Announces Target Price $11
    \u5e02\u573a\u8d44\u8baf · 2025/12/23
  • 评级变动
    Oppenheimer Maintains Savara(SVRA.US) With Buy Rating, Raises Target Price to $9
    \u5e02\u573a\u8d44\u8baf · 2025/11/14
  • 评级变动
    Guggenheim Maintains Savara(SVRA.US) With Buy Rating, Raises Target Price to $11
    \u5e02\u573a\u8d44\u8baf · 2025/9/9
  • 评级变动
    LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Cuts Target Price to $11
    \u5e02\u573a\u8d44\u8baf · 2025/10/14
  • 评级变动
    LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Cuts Target Price to $9
    \u5e02\u573a\u8d44\u8baf · 2026/4/16
  • 评级变动
    Oppenheimer Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $11
    \u5e02\u573a\u8d44\u8baf · 2026/6/3
  • LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10
    \u5e02\u573a\u8d44\u8baf · 2026/8/13
  • 评级变动
    Wells Fargo Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9
    \u5e02\u573a\u8d44\u8baf · 2026/5/22
  • 评级变动
    H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $8
    \u5e02\u573a\u8d44\u8baf · 2025/11/14
  • 评级变动
    Citizens JMP Maintains Savara(SVRA.US) With Buy Rating, Raises Target Price to $11
    \u5e02\u573a\u8d44\u8baf · 2025/10/23
  • 评级变动
    LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Raises Target Price to $10
    \u5e02\u573a\u8d44\u8baf · 2026/5/21
  • Guggenheim Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $11
    \u5e02\u573a\u8d44\u8baf · 2026/8/21
  • 评级变动
    LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9
    \u5e02\u573a\u8d44\u8baf · 2026/5/16
  • A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $9 to $11
    \u5e02\u573a\u8d44\u8baf · 2026/8/12
  • 评级变动
    LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $11
    \u5e02\u573a\u8d44\u8baf · 2026/4/11
  • Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16
    \u5e02\u573a\u8d44\u8baf · 2026/8/26
  • 评级变动
    Oppenheimer Maintains Savara(SVRA.US) With Buy Rating, Raises Target Price to $11
    \u5e02\u573a\u8d44\u8baf · 2026/4/25
  • 评级变动
    A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $9 to $16
    \u5e02\u573a\u8d44\u8baf · 2026/5/13
  • H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10
    \u5e02\u573a\u8d44\u8baf · 2026/6/15
  • 评级变动
    H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Raises Target Price to $10
    \u5e02\u573a\u8d44\u8baf · 2025/12/23

新闻标题为自动聚合内容,未经我们团队独立核实或编辑。

报价时间 2026-10-16 20:01:08 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

萨瓦拉制药 讨论区 0 条评论

发表评论